TABLE 1.

Univariate analysis of factors associated with all-cause 14-day mortality for 162 patients with K. pneumoniae bloodstream infections

VariableNo. of patients/total (%)OR (95% CI)P
Survived (n = 131)Died (n = 31)
Host-related
    Mean age (yr) ± SD59.01 ± 18.1665.74 ± 16.941.02 (1.00-1.05)0.06
    Gender
        Male85/103 (82.5)18/103 (17.5)0.75 (0.34-1.67)0.48
        Female46/59 (78.0)13/59 (22.0)
    Comorbidities
        ≥261/79 (77.2)18/79 (22.8)1.59 (0.72-3.51)0.25
        <270/83 (84.3)13/83 (15.7)
    Rapidly fatal underlying disease
        Yes23/33 (68.7)10/33 (30.3)2.23 (0.93-5.38)0.07
        No108/129 (83.7)21/129 (16.3)
    Pitt bacteremia score
        ≥451/71 (71.8)20/71 (28.2)2.85 (1.26-6.45)0.01
        <480/91 (87.9)11/91 (12.1)
Infection related
    ESBL production
        Yes50/62 (80.6)12/62 (19.4)1.02 (0.46-2.29)0.95
        No81/100 (81.0)19/100 (19.0)
    VIM-1 production
        Yes51/67 (76.1)16/67 (23.9)1.67 (0.76-3.68)0.20
        No80/95 (84.2)15/95 (15.8)
    MIC of carbapenems
        >4 μg/mla8/14 (57.1)6/14 (42.9)3.69 (1.18-11.57)0.02
        ≤4 μg/ml123/148 (83.1)25/148 (16.9)
    Source of bacteremia
        Nonurinary110/140 (78.6)30/140 (21.4)5.73 (0.74-44.32)0.09
        Urinary21/22 (95.5)1/22 (4.5)
    Polymicrobial bacteremia
        Yes23/34 (67.6)11/34 (32.4)2.58 (1.09-6.12)0.03
        No108/128 (84.4)20/128 (15.6)
Treatment related
    Appropriate empirical therapy
        No20/29 (69.0)9/29 (31.0)2.27 (0.91-5.64)0.08
        Yes111/133 (83.5)22/133 (16.5)
    Appropriate definitive therapy
        No17/25 (68)8/25 (32)2.33 (0.90-6.05)0.08
        Yes114/137 (83.2)23/137 (16.8)
  • a The MICs of both imipenem and meropenem were >4 μg/ml.